UB Paderborn / Katalog / Suche / in CDI

Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial

Respiratory research, 2020-10, Vol.21 (1), p.280-280, Article 280

2020

Volltextzugriff (PDF)

Indicateurs de risque de complications cardiopulmonaires détectés grâce à la réalisation d’un ECG chez des patients atteints de bronchopneumopathie chronique obstructive : analyse post-hoc de l’étude IMPACT

Revue des maladies respiratoires actualités, 2024-01, Vol.16 (1), p.199-200

2024

Volltextzugriff (PDF)

Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement

International journal of chronic obstructive pulmonary disease, 2021-01, Vol.16, p.1215-1226

2021

Volltextzugriff (PDF)

Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model

International journal of chronic obstructive pulmonary disease, 2021-01, Vol.16, p.3105-3118

2021

Volltextzugriff (PDF)

Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD

International journal of chronic obstructive pulmonary disease, 2018-01, Vol.13, p.203-215

2018

Volltextzugriff (PDF)

Relation entre le test d’évaluation de la BPCO et le questionnaire respiratoire de St George chez les patients atteints de BPCO : une analyse post-hoc des essais IMPACT, FULFIL et EMAX

Revue des maladies respiratoires actualités, 2022-01, Vol.14 (1), p.92-92

2022

Volltextzugriff (PDF)

Transdermal Delivery of Ibuprofen Utilizing a Novel Solvent-Free Pressure-sensitive Adhesive (PSA): TEPI® Technology

Journal of pharmaceutical innovation, 2018, Vol.13 (1), p.48-57

2018

Volltextzugriff (PDF)

Détérioration cliniquement importante dans la BPCO comme critère de réponse à un ou deux bronchodilatateurs avec et sans corticostéroïdes inhalés

Revue des maladies respiratoires, 2017-01, Vol.34, p.A173-A173

2017

Volltextzugriff (PDF)

Analyse comparative en sous-groupe de umeclidinium/vilanterol vs. tiotropium chez des patients BPCO

Revue des maladies respiratoires, 2017-01, Vol.34, p.A150-A150

2017

Volltextzugriff (PDF)

Comparaison de l’efficacité de Umeclidinium/Vilanterol, Umeclidinium et Salmeterol chez les patients ayant une bronchopneumopathie chronique obstructive ne recevant pas de corticoïdes inhalés : étude EMAX

Revue des maladies respiratoires actualités, 2020-01, Vol.12 (1), p.189-190

2020

Volltextzugriff (PDF)

P122 Combination therapy with inhaled salmeterol plus fluticasone propionate is more effective than salmeterol alone in reducing the risk of clinically important deterioration in COPD: A post-hoc analysis of the TORCH trial: Abstract P122 Table 1

Thorax, 2015-12, Vol.70 (Suppl 3), p.A136-A137

2015

Volltextzugriff (PDF)

P122 Combination therapy with inhaled salmeterol plus fluticasone propionate is more effective than salmeterol alone in reducing the risk of clinically important deterioration in COPD: A post-hoc analysis of the TORCH trial

Thorax, 2015-12, Vol.70 (Suppl 3), p.A136

2015

Volltextzugriff (PDF)

S57 Short-term clinically important deterioration predicts long-term clinical outcome in COPD patients: A post-hoc analysis of the TORCH trial

Thorax, 2015-12, Vol.70 (Suppl 3), p.A34-A35

2015

Volltextzugriff (PDF)

D36 ALL TOGETHER NOW: COPD TREATMENT WITH LONG-ACTING BETA AGONISTS AND LONG-ACTING MUSCARINIC ANTAGONISTS: Efficacy Of Umeclidinium/vilanterol Compared With Tiotropium: Results From A Pooled Analysis Of Three Phase Iii, Randomized Studies

American journal of respiratory and critical care medicine, 2015-01, Vol.191, p.1

2015

Volltextzugriff (PDF)

PRS10 Economic Evaluation of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol in a UK COPD Population at Low Risk of Exacerbations Using the GALAXY Model

Value in health, 2021-06, Vol.24, p.S214-S214

2021

Volltextzugriff (PDF)

Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial

International journal of chronic obstructive pulmonary disease, 2021-01, Vol.16, p.1939-1956

2021

Volltextzugriff (PDF)

Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials

International journal of chronic obstructive pulmonary disease, 2021, Vol.16, p.1925-1938

2021

Volltextzugriff (PDF)

D37 HELP: ADVANCES IN COPD THERAPEUTICS: Triple Therapy With Umeclidinium Plus Fixed-Combination Inhaled Corticosteroid/long-Acting Beta-Agonist Therapy In Chronic Obstructive Pulmonary Disease: Pooled Results In Placebo-Controlled Trials

American journal of respiratory and critical care medicine, 2015-01, Vol.191, p.1

2015

Volltextzugriff (PDF)

D36 ALL TOGETHER NOW: COPD TREATMENT WITH LONG-ACTING BETA AGONISTS AND LONG-ACTING MUSCARINIC ANTAGONISTS: Can Dual Long-Acting Bronchodilator Therapy Prevent Clinically Important Deteriorations In Chronic Obstructive Pulmonary Disease? A Post Hoc Analysis Of The Zep117115 Trial

American journal of respiratory and critical care medicine, 2015-01, Vol.191, p.1

2015

Volltextzugriff (PDF)

P144 A comparison of shuttle walking test endpoints in exercise studies in patients with COPD: Abstract P144 Table 1

Thorax, 2015-12, Vol.70 (Suppl 3), p.A149-A149

2015

Volltextzugriff (PDF)

P144 A comparison of shuttle walking test endpoints in exercise studies in patients with COPD

Thorax, 2015-12, Vol.70 (Suppl 3), p.A149

2015

Volltextzugriff (PDF)

Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol

International journal of chronic obstructive pulmonary disease, 2016-06, Vol.2016 (Issue 1), p.1413-1424

2016

Volltextzugriff (PDF)

Factors in Canada's future

Municipal Review of Canada, 1943-10, p.7-8

Tombs, L C

1943

Volltextzugriff (PDF)

The port of Montreal: the history and facilities of a great inland harbour

Dock & Harbour Authority, 1928-07, Vol.8, p.35-44

Tombs, L C

1928

Volltextzugriff (PDF)

The problems of Canadian transportation: with some notes on the economic relationship of railways and ports in the dominion

Dock and Harbour Authority, 1927-08, Vol.7, p.259-262

Tombs, L C

1927

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial

Indicateurs de risque de complications cardiopulmonaires détectés grâce à la réalisation d’un ECG chez des patients atteints de bronchopneumopathie chronique obstructive : analyse post-hoc de l’étude IMPACT

Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement

Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model

Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD

Relation entre le test d’évaluation de la BPCO et le questionnaire respiratoire de St George chez les patients atteints de BPCO : une analyse post-hoc des essais IMPACT, FULFIL et EMAX

Transdermal Delivery of Ibuprofen Utilizing a Novel Solvent-Free Pressure-sensitive Adhesive (PSA): TEPI® Technology

Détérioration cliniquement importante dans la BPCO comme critère de réponse à un ou deux bronchodilatateurs avec et sans corticostéroïdes inhalés

Analyse comparative en sous-groupe de umeclidinium/vilanterol vs. tiotropium chez des patients BPCO

Comparaison de l’efficacité de Umeclidinium/Vilanterol, Umeclidinium et Salmeterol chez les patients ayant une bronchopneumopathie chronique obstructive ne recevant pas de corticoïdes inhalés : étude EMAX

P122 Combination therapy with inhaled salmeterol plus fluticasone propionate is more effective than salmeterol alone in reducing the risk of clinically important deterioration in COPD: A post-hoc analysis of the TORCH trial: Abstract P122 Table 1

P122 Combination therapy with inhaled salmeterol plus fluticasone propionate is more effective than salmeterol alone in reducing the risk of clinically important deterioration in COPD: A post-hoc analysis of the TORCH trial

S57 Short-term clinically important deterioration predicts long-term clinical outcome in COPD patients: A post-hoc analysis of the TORCH trial

D36 ALL TOGETHER NOW: COPD TREATMENT WITH LONG-ACTING BETA AGONISTS AND LONG-ACTING MUSCARINIC ANTAGONISTS: Efficacy Of Umeclidinium/vilanterol Compared With Tiotropium: Results From A Pooled Analysis Of Three Phase Iii, Randomized Studies

PRS10 Economic Evaluation of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol in a UK COPD Population at Low Risk of Exacerbations Using the GALAXY Model

Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial

Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials

D37 HELP: ADVANCES IN COPD THERAPEUTICS: Triple Therapy With Umeclidinium Plus Fixed-Combination Inhaled Corticosteroid/long-Acting Beta-Agonist Therapy In Chronic Obstructive Pulmonary Disease: Pooled Results In Placebo-Controlled Trials

D36 ALL TOGETHER NOW: COPD TREATMENT WITH LONG-ACTING BETA AGONISTS AND LONG-ACTING MUSCARINIC ANTAGONISTS: Can Dual Long-Acting Bronchodilator Therapy Prevent Clinically Important Deteriorations In Chronic Obstructive Pulmonary Disease? A Post Hoc Analysis Of The Zep117115 Trial

P144 A comparison of shuttle walking test endpoints in exercise studies in patients with COPD: Abstract P144 Table 1

P144 A comparison of shuttle walking test endpoints in exercise studies in patients with COPD

Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol

Factors in Canada's future

The port of Montreal: the history and facilities of a great inland harbour

The problems of Canadian transportation: with some notes on the economic relationship of railways and ports in the dominion

Aktive Filter

Suchergebnisse filtern